chrisvoncsefalvay/vaers-outcomes huggingface dataset:
significant bruising patterns with red dots on her right arm near her vaccination site; red dots on her right arm near her vaccination site; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE BRUISING (significant bruising patterns with red dots on her right arm near her vaccination site) and VACCINATION SITE ERYTHEMA (red dots on her right arm near her vaccination site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002A21A and 028L20A) for COVID-19 vaccination.     Concurrent medical conditions included Autoimmune disorder.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE BRUISING (significant bruising patterns with red dots on her right arm near her vaccination site) and VACCINATION SITE ERYTHEMA (red dots on her right arm near her vaccination site). At the time of the report, VACCINATION SITE BRUISING (significant bruising patterns with red dots on her right arm near her vaccination site) and VACCINATION SITE ERYTHEMA (red dots on her right arm near her vaccination site) outcome was unknown.            Concomitant product use was not provided by the reporter.   Treatment information was not provided.  Patient reported she is a veterinarian so explained she understands the medical world and she has followed up with rheumatologist and dermatologist and neither of her doctors can explain hey symptoms.   Patient reported two weeks after her second dose she had significant bruising patterns with red dots on her right arm near her injection site.  She explained that they were not raised or elevated or itchy. Patient reported this went away, then two weeks later came back but was not as intense. Patient reported her symptoms then went away and two weeks later returned again. Patient reported she has an autoimmune disorder.  Patient explained that since being vaccinated, anytime she has a bump or runs into something or cuts herself on a thorn, a similar looking bruise pattern/red dot appeared.
Information has been received from a consumer concerning his daughter, an approximately 24 month old female patient with no pertinent medical history and no drug reactions/allergies who was vaccinated with a second dose of MMR II (lot number, route and site not reported) sometime in 1987. There was no concomitant medication. About a month after receiving the second dose of MMR II, the patient's brain began to swell and she had several grand mal seizures. The patient was then sent to hospital because she stopped breathing and was put on a respirator for about a day and a half. The consumer reported that the patient was in hospital for about two weeks and after being taken off of the respirator, the patient could not speak and it looked like she may have DOWN's syndrome. No laboratory diagnostic study was performed. The consumer reported that the physician did not know that what caused the patient's brain to swell. After two years treatment, type of treatment was unspecified, the patient had recovered. No further information is available.
As administered Tdap on 5-27-10 at about 11:30. States about 2 hrs later she started with a HA. She went home her HA was worsening. She went to sleep when she woke up she was having difficulty breathing; as she went to blow her nose she felt phlegm coming up from chest area with a burning sensation. Her mucous was pinkish tinged. She took Motrin and drank fluids throughout the day, was hoarse and felt swelling to throat. Did not go to ER thought it was a cold. Today continues with symptoms. No fever sent to see her PCP.
4/25/07 24 hrs after Rotateq profuse Diarrhea and fever (11-12 watery stools). Some til 5/3/07 when blood seen. Patient recovered by 5/7/07 but also had facial rash now.  6/5/07 Received vax records from PCP which provide additional vaccines received along w/Rotateq, dose 1, Lot # as reported.  VAERS database updated w/same.
This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided. On 20-MAR-2017,  the patient was vaccinated with one of the improperly stored doses of M-M-R II  lot # M028130, expiration date 03-MAR-2018 (strength, dose number, route and anatomical location was not provided) for prophylaxis. The dose of M-M-R II was in temperature of 48 °F (Fahrenheit ) degree for 52 hours. There was previous temperature excursion as 32°F (Fahrenheit ) for 15.5 hours. No adverse effect was reported and digital data logger was involved. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1704USA000553: US-009507513-1704USA001060: US-009507513-1704USA001058.
This spontaneous case reported by an other healthcare professional, describes the occurrence of administered expired product (expired doses administered to patients) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 041C21A) for COVID-19 immunization. No medical history reported. On Nov 5, 2021, patient received the third dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On Nov 5, 2021, patient administered expired product (expired doses administered to patients). On Nov 5, 2021, administered expired product (expired doses administered to patients) resolved. The reporter did not provide any causality assessments, concomitant medication or treatment information.
Red rash at site of vaccine. Warm to touch, slightly swollen and itchy. About 4 inches long 3 inches wide
This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): MOD21-122727 (Moderna). A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SKIN DISCOLOURATION (non-serious), outcome "unknown", described as "Her roommate's arm was black and blue after he received his Pfizer shot". Additional information: After reporting her brothers adverse events as well as her own, the caller states that her roommate's arm was black and blue after he received his Pfizer shot. She states she and her room mate were not sick after receiving their injections. Both the caller and the room mate received the Pfizer vaccine. There is no concomitant list. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Does the vaccine have deadly side effects for people with heart diease; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Does the vaccine have deadly side effects for people with heart diease) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Does the vaccine have deadly side effects for people with heart diease). At the time of the report, VACCINATION COMPLICATION (Does the vaccine have deadly side effects for people with heart diease) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported No treatment medications were reported.
Pt experienced headache the evening of injection. Pt observed arm which was red, raised and tender at injection site. Pt was seen by physician one day post vax. Area at injection sit 1.5 - 2" circumference 3". Pt treated with Trimamcinolone cream.
Secondary Parkinsonism after J&J; hs-CRP and IL-6 elevated
Patient reports having right calf pain that she sought medical treatment for on approximately 7/16/2021 and was told she had "microclots" in her R leg.  Patient reports having a follow-up ultrasound of her right leg in late July early August 2021 due to continued pain in her calf and swelling of her right ankle and was diagnosed with DVT, deep veing thrombosis, and was told there were 4 clots in her leg. Patient was placed on eliquis (apixaban) for treatment. Patient reports being very healthy and that she has never had any clotting problems prior to this event. As of 8/9/21 patient still has ankle swelling but otherwise starting to improve overall.
Experiencing muscle twitching in his right arm; muscle spasm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 57 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 02Sep2021 10:00 (Lot number: FC3182) at the age of 57 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "allergic to shellfish" (unspecified if ongoing); "Blood pressure high" (unspecified if ongoing). Concomitant medication(s) included: LOSARTAN taken for hypertension (ongoing); TAMSULOSIN taken for diuretic therapy (ongoing). The following information was reported: MUSCLE TWITCHING (non-serious) with onset 02Sep2021, outcome "not recovered", described as "Experiencing muscle twitching in his right arm"; MUSCLE SPASMS (non-serious) with onset Sep2021, outcome "unknown", described as "muscle spasm".  Additional information: It was reported that, the patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was reported that on vaccination day evening he started experiencing muscle twitching in his right arm which was the arm he was vaccinated it had stayed the same, occurring 3-4 times a day.  Follow-up attempts are completed. No further information is expected.
Heavy chill headache; Heavy chill headache; sweetness; This is spontaneous report from a contactable consumer (patient, self-reported).   A 51-year-old male patient (age at vaccination: 51 year) received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via an unspecified route of administration, in Arm Right, on 13Mar2021 at 07:15 AM, as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient reported that on 17Mar2021 at 05:00 PM, he had heavy chill headache and sweetness. The events were resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the adverse event. Outcome of the events was unknown.  Information about the lot/batch number has been requested.  Follow-up attempts are completed. No further information is expected.
Hearing loss; no treatment, because hearing had started to return by the time I was seen by a medical professional two days later
fatigue; Headaches; muscle soreness; This is a spontaneous report from a contactable consumer (patient) from the Pfizer-sponsored program, Support. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose number unknown, single for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced fatigue, headaches and muscle soreness 4 days after the vaccine was administered on an unspecified date. The outcome of the events was unknown.  No follow-up attempts are possible; information about batch/lot number cannot be obtained. No further information is expected.
rash; shingles; This is a spontaneous report from a Pfizer-sponsored program Pfizer First Connect. A contactable nurse reported that a 43-year-old female patient started to receive BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 22Dec2020 at single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced developed a rash and shingles in Dec2020. The action taken in response to the events for bnt162b2 was not applicable. The outcome of events was unknown.  Information about batch/lot number has been requested.
Site: Itching at Injection Site-Mild, Site: Redness at Injection Site-Mild, Systemic: Allergic: Itch Generalized-Mild, Additional Details: Patient called about a red itchy rash that appeared about 1 week after the 1st dose of the moderna covid-19 vaccine. She has had it for a couple days now.
High fever, headache, muscle and joint aches, and weakness. Started Friday evening and lasted through Sunday afternoon.
On 7/16 and 7/17 had mild localized rash to left upper arm (site of vaccine), treated with Benadryl Cream.  On 7/19 noticed spreading rash to upper thighs, stomach, top of right foot.  Rash red and papular.  Went to Urgent Care about 1:30 PM and Dr. told her that she was allergic to Varicella Vaccine.  Given Prednisone 20 mg, two tablets once a day for 5 days.  Today on 7/22 rash is faint, pale and almost gone. States it still itches but is better.  Localized reaction to left upper arm is gone completely.  Did not have a fever during this time.  No other problems other than rash.
Pt accidentally received the 5-11 covid-19 vaccination dose instead of the 12 and up dose.
Body aches, chills, fever, sore throat, cough, headache, painful muscle and joint movements, painful eye movements, watery eyes
Parestheris: pain - Information has been received from a physician concerning a 14 year old female patients who in approximatley 1999 was vaccianted with varicella virus vaccine live.  On approximately 29 Apr 2000 the patient began to experienced prodromal symtoms of burning in T9 and t10 area.  At the time of reporting no rash was present it was noted that the patient feels sunburn and her skin is tender to the touch.  unspecified medial attention was sought.
Decreased activity, rash, temperature of 105F, seizure, pharyngitis and poor appetite.
COVID+ 1/7/2023.  Vaccination Status - J&J x2   BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider at Discharge: PA-C Admission Date: 1/7/2023 Discharge Date: 1/19/2023   HOSPITAL PROBLEMS 1. Covid-19 Infection 2. Atelectasis 3. Afib 4. Hypothyroidism 5. Depression 6. Hyperglycemia secondary to steroid use 7. Prediabetes 8. Hyponatremia DETAILS OF HOSPITAL STAY: HOSPITAL COURSE: Patient is a 87 y.o. female with history of AFib RVR on Eliquis.  Presented to emergency department with 5 days of headache and nausea and cough.  She was COVID positive, tachycardic in the 130s and afebrile.  Initial labs including complete blood count, procalcitonin, UA and CRP were normal.  She did have mild hyponatremia.  She required 2 L of nasal cannula in the emergency department.  CTA thorax negative for pulmonary embolus but showed bibasilar atelectasis with chronic left-sided hiatal hernia.  She was admitted for acute hypoxic respiratory failure in the setting of COVID-19.   While admitted she received remdesivir for 5 days. She was also on Decadron 6 mg for 8 days.  She was intermittently confused however respiratory status improved overall.  She was weaned to room air during on day 2 of admission.  She did require 2 L nasal cannula at night, baseline is CPAP.  She would often refuse her CPAP when offered.   Course was complicated by persistently elevated heart rate above 100 reaching 130 at times.  She was initially on home dose of metoprolol 75 mg twice a day.  There was no improvement with increase to 100 mg twice a day.  Eventually Cardizem 120 mg daily was added on 01/10.  Heart rate significantly improved and was persistently in the 80s.   She was evaluated by PT/OT who recommended subacute rehab.  She was medically stable for discharge to SAR on 01/19/2023.
Exposure to COVID-19 virus  Lab test positive for detection of COVID-19 virus  Cough  Other fatigue
Extreme injection site pain. Headache. Nausea. Chills. Fever to 101 F. Fatigue. Muscle and joint pain. Loss of appetite. Still ongoing on day 2. I wonder if people who have had the virus should be being told to get the vaccine since I suspect intense reaction is due to pre existing immunity.
the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day; the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day; This spontaneous case was reported by a patient and describes the occurrence of RHINORRHOEA (the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day) and COVID-19 (the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day) in an elderly male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7144B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In February 2023, the patient experienced RHINORRHOEA (the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day) and COVID-19 (the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day). At the time of the report, RHINORRHOEA (the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day) and COVID-19 (the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In February 2023, SARS-CoV-2 test: Positive.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  Reportedly, the patient received his first Moderna COVID-19 vaccine on 15-Jan-2021 with lot number 026L20A. Patient received in his left arm. The patient had no adverse reactions or side effects to 1st dose.  The patient received his second Moderna COVID-19 vaccine on 02-Feb-2021 with lot number 029K20A. Patient received in his left arm. The patient had no adverse reactions or side effects to 2nd dose.  The patient received his first booster dose of Moderna COVID-19 vaccine on 24-Aug-2021 with lot number 002F21A. Patient received in his left arm. The patient had no adverse reactions or side effects to first booster dose.  The patient received his second booster dose of Moderna COVID-19 vaccine on 03-Mar-2022 with lot number 045L21A. Patient received in his left arm. The patient had no adverse reactions or side effects to second booster dose.  The patient received his third booster dose of Moderna COVID-19 vaccine on 07-Sep-2022 with lot number AS7144B. Patient received in his left arm. The patient had no adverse reactions or side effects to third booster dose.  In Feb-2023 the patient had a very mild case of COVID-19, the patient tested positive and had the sniffles for one day.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-744661 (Patient Link).
bilateral eyelids itched; Bilateral eyelids swelling; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Jul2021 at 19:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included milk allergy (Dairy allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) and paracetamol (TYLENOL) all from an unknown date for an unspecified indication. On 12Jul2021 at 20:00, the patient experienced eyelids itched and became swollen, bilateral within two hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures  were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events eyelids itched and became swollen, bilateral was recovered on an unspecified date in Jul2021.  The lot number for BNT162b2 was not provided and will be requested during follow up.